Company news
Viking Therapeutics, Inc. (NASDAQ:VKTX) news
Viking Therapeutics, Inc. news releases on 6ix. Latest, Oct 6, 2026: Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial…
Press releases & updates
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
October 5, 2026
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
October 6, 2026
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
September 28, 2026
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
September 23, 2026
Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
September 22, 2026
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
July 29, 2026
Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
July 23, 2026
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
July 22, 2026
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
June 24, 2026
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
June 11, 2026
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
May 5, 2026
Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
April 29, 2026
Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
April 22, 2026
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
March 25, 2026
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
February 11, 2026
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
February 4, 2026
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
January 11, 2026
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
January 7, 2026
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
January 6, 2026
Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 4, 2026
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
November 24, 2025
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
November 18, 2025
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
November 5, 2025
Viking Therapeutics to Participate at Upcoming Investor Conferences
November 3, 2025
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025
October 28, 2025
Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 21, 2025
Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
October 20, 2025
Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025
October 14, 2025
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
August 18, 2025
Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
July 22, 2025
Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025
July 15, 2025
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
June 24, 2025
Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
April 22, 2025
Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025
April 15, 2025
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
March 25, 2025
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
March 10, 2025
CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations
March 10, 2025
Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
February 4, 2025
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025
January 28, 2025
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
January 7, 2025
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 5, 2025
Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
November 18, 2024
Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
November 11, 2024
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024
November 3, 2024
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024
October 27, 2024
Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
October 22, 2024
Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024
October 15, 2024
Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
October 8, 2024
Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference
August 27, 2024
Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
July 23, 2024